Emily Nguyen
Medical · Richardson, TXNPI 1902528391
Payments from drug & device makers
Across 340 payments — averaging $21.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$878
- Argenx US, Inc.$534
- Pfizer$435
- Genentech USA, Inc.$414
- Lundbeck LLC$382
- UCB, Inc.$373
- plus $4K from 38 others
What the payments were for
- Food & beverage$7,13899%
- Education$561%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,194 in reported general payments places this provider in the 85th percentile of 1,490 medical providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BriviactBrivaracetam | 31 | $57,541 |
| RexultiBrexpiprazole | 17 | $31,029 |
| Nurtec OdtRimegepant Sulfate | 13 | $22,977 |
| NamzaricMemantine Hcl/Donepezil Hcl | 12 | $21,068 |
| AdlarityDonepezil Hcl | 18 | $7,984 |
| Memantine Hcl | 200 | $7,895 |
| Carbidopa-Levodopa ErCarbidopa/Levodopa | 54 | $5,113 |
| Primidone | 80 | $3,952 |
| Ropinirole Hcl | 92 | $3,674 |
| Lacosamide | 18 | $3,309 |
| Gabapentin | 119 | $2,338 |
| Galantamine Hbr | 26 | $2,293 |
| Donepezil Hcl | 185 | $2,000 |
| Levetiracetam | 39 | $1,680 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 55 | $1,561 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| UCB, Inc.Briviact | $373 | $57,54131 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $328 | $31,02917 claims |
| PfizerNurtec Odt | $435 | $22,97713 claims |
| AbbVieNamzaric | $878 | $21,06812 claims |
| Corium, LLCAdlarity | $177 | $7,98418 claims |
| Upsher-smith Laboratories LLCTopiramate | $38 | $20611 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,490 medical providers in Texas.
Other medical in Richardson
- Jose de la CerdaSan Antonio$1.1M
- Mark DavisFort Worth$1M
- Joey Dixon-JulianBoerne$458K
- Terry FaleyeKingwood$243K
- Kimberly PoarchDallas$166K
- Erin DuhaimeDallas$150K
- Courtney AldridgeSan Antonio$129K
- Shakira CabreraSan Antonio$116K
- Danny DeckardDallas$101K
- Janine ShinnDallas$84K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.